Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Current Assets (2023 - 2025)

Ascentage Pharma Group International posted quarterly Current Assets of $415.1 million for Q4 2025, up 102.27% year-on-year from $205.2 million in Q4 2024, and up 55.79% on a QoQ basis from $266.4 million in Q2 2025.

Ascentage Pharma Group International (AAPG) has 3 years of Current Assets data on file, last reported at $415.1 million in Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 102.27% year-over-year to $415.1 million; the trailing twelve-month figure through Dec 2025 stood at $415.1 million (up 102.27% YoY), and the FY2025 full-year result was $421.0 million, up 108.46% from the prior year.
  • Current Assets for Q4 2025 stood at $415.1 million, up from $266.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $415.1 million in Q4 2025 and bottomed at $186.7 million in Q4 2023.
  • The 3-year median for Current Assets is $235.8 million (2024), against an average of $268.4 million.
  • The widest annual swing landed in 2024, when Current Assets gained 9.93%; it then jumped 102.27% in 2025.
  • A 3-year view of Current Assets shows it stood at $186.7 million in 2023, then grew by 9.93% to $205.2 million in 2024, then surged by 102.27% to $415.1 million in 2025.
  • The last three Current Assets figures came in at $415.1 million (Q4 2025), $266.4 million (Q2 2025), and $205.2 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Assets (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - 10.37 Mn
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - 37.31 Mn
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn 1.25 Bn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - 73.04 Mn
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - 3.59 Mn
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 11.73 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 18.21 Bn
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 4.22 Bn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn - 415.11 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 415.11 Mn
Jun 30, 2025 266.45 Mn
Dec 31, 2024 205.23 Mn
Dec 31, 2023 186.69 Mn